^
Association details:
| Biomarker: | CLDN18.2 overexpression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Vyloy (zolbetuximab-clzb) (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
Published date:
05/19/2021
Excerpt:
This study assessed antitumor activity and safety/tolerability of first-line zolbetuximab+mFOLFOX6 (Cohort 2 in NCT03505320) in G/GEJ with high CLDN18.2 expression....promising antitumor activity with zolbetuximab+mFOLFOX6 in metastatic or locally advanced G/GEJ.
Secondary therapy:
Modified FOLFOX6
DOI:
10.1200/JCO.2021.39.15_suppl.e16063
Trial ID:
Source:
Title:
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
Excerpt:
...patients with moderate-to-high CLDN18.2 expression in ≥70% of tumour cells, ORR was 14% (n = 4/29)...Zolbetuximab monotherapy was well tolerated and exhibited antitumour activity in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinomas...
DOI:
10.1093/annonc/mdz199
Trial ID:
